Institute of Sleep Disorders, Loewenstein Rehabilitation Center, Raanana, Israel.
Department of Outpatient Medical Rehabilitation, Loewenstein Rehabilitation Center, Raanana, Israel.
J Clin Sleep Med. 2022 Oct 1;18(10):2503-2506. doi: 10.5664/jcsm.10134.
Narcolepsy is a rare condition in Israel. Currently, the incidence of narcolepsy following SARS-CoV-2 vaccination in Israel is unknown. We are reporting a case report of a 51-year-old woman of Ashkenazi Jewish descent who was evaluated for complaints of excessive daytime sleepiness and relative functional decline that immediately followed receipt of the Pfizer/BioNTech SARS-CoV-2 vaccination. Evaluation of patient-reported data with polysomnography and multiple sleep latency test was consistent with narcolepsy with cataplexy, meeting the criteria for a diagnosis of type 1 narcolepsy. Further investigation included human leukocyte antigen testing. Prior studies have demonstrated genetic, immunological, and environmental factors associated with narcolepsy following other vaccinations. This case is a valuable contribution to the literature as there are no prior reports of type 1 narcolepsy following SARS-CoV-2 vaccination in the State of Israel.
Mahamid A, Bornstein RJ, Amir H. Pfizer/BioNTech SARS-CoV-2 vaccine as a potential trigger for the development of narcolepsy: a case report. . 2022;18(10):2503-2506.
嗜睡症在以色列较为罕见。目前，以色列尚不清楚接种 SARS-CoV-2 疫苗后嗜睡症的发病率。我们报告了一例 51 岁的阿什肯纳兹犹太血统女性病例，她因白天过度嗜睡和接种辉瑞/生物技术公司 SARS-CoV-2 疫苗后立即出现相对功能下降而接受评估。对患者报告数据的多导睡眠图和多次睡眠潜伏期试验评估与伴有猝倒的发作性睡病一致，符合 1 型发作性睡病的诊断标准。进一步的调查包括人类白细胞抗原检测。先前的研究表明，接种其他疫苗后发生嗜睡症与遗传、免疫和环境因素有关。本病例为文献做出了有价值的贡献，因为在以色列，尚无 SARS-CoV-2 疫苗接种后发生 1 型发作性睡病的报告。
Mahamid A, Bornstein RJ, Amir H. Pfizer/BioNTech SARS-CoV-2 vaccine as a potential trigger for the development of narcolepsy: a case report.. 2022;18(10):2503-2506.
